TrialHaematologica2022

Clofarabine increases the eradication of minimal residual disease of primary B-precursor acute lymphoblastic leukemia compared to high-dose cytarabine without improvement of outcome. Results from the randomized clinical trial 08-09 of the Cooperative Acute Lymphoblastic Leukemia Study Group.

Gabriele Escherich et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.